IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 705 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  »   My Preferences 
  »   Manuscript submission

 


This article has been cited by
1Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)
Masaya Sakamoto,Rimei Nishimura,Taiga Irako,Daisuke Tsujino,Kiyotaka Ando,Kazunori Utsunomiya
Cardiovascular Diabetology.2012;11(1)92
[DOI]
2Flavonoid rich fraction of Pilea microphylla (L.) attenuates metabolic abnormalities and improves pancreatic function in C57BL/KsJ-db/db mice
P. Bansal,P. Paul,G. Shankar,D. Munjal,P.G. Nayak,K.I. Priyadarsini,M.K. Unnikrishnan
Biomedicine & Preventive Nutrition.2011;1(4)268
[DOI]
3Alkaloid Fraction of Litsea glutinosa Leaves Provides an Important Precursor for Inhibition of Dipeptidyl Peptidase 4 Activity
S W Kisnawaty,P Nityasewaka,B A R Sukma,A V Putrinadia,T Ma’rifah,D G Tamtomo,D Indarto
IOP Conference Series: Materials Science and Engineering.2019;546(4)062013
[DOI]
4Influence of the cellular environment on ligand binding kinetics at membrane-bound targets
Patrick M.L. Vanderheyden,Nerdjes Benachour
Bioorganic & Medicinal Chemistry Letters.2017;27(16)3621
[DOI]
5Influence of the cellular environment on ligand binding kinetics at membrane-bound targets
Shujaath Mehdi
Bioorganic & Medicinal Chemistry Letters.2013;27(16)81
[DOI]
6Pharmacological potential of novel agonists for FFAR4 on islet and enteroendocrine cell function and glucose homeostasis
A.G. McCloskey,M.G. Miskelly,P.R. Flatt,A.M. McKillop
European Journal of Pharmaceutical Sciences.2020;142(16)105104
[DOI]
7Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
Wolfgang Kothny,Valentina Lukashevich,James E. Foley,Marc S. Rendell,Anja Schweizer
Diabetologia.2015;58(9)2020
[DOI]
8CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell function
A.G. McCloskey,M.G. Miskelly,C.B.T. McMullen,M.A. Nesbit,K.A. Christie,A.I. Owolabi,P.R. Flatt,A.M. McKillop
Peptides.2020;58(9)170251
[DOI]
9Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
B. Ahrén,A. Schweizer,S. Dejager,E. B. Villhauer,B. E. Dunning,J. E. Foley
Diabetes, Obesity and Metabolism.2011;13(9)775
[DOI]
10Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222
Robert J. Greene,Hua Tu,John P. Gibbs,J. Greg Slatter
Xenobiotica.2011;41(11)945
[DOI]
11A novel self-sufficient biocatalyst based on transaminase and pyridoxal 5'-phosphate covalent co-immobilization and its application in continuous biosynthesis of sitagliptin
Xiao-Jian Zhang,Hao-Hao Fan,Nan Liu,Xin-Xin Wang,Feng Cheng,Zhi-Qiang Liu,Yu-Guo Zheng
Enzyme and Microbial Technology.2019;130(11)109362
[DOI]
12The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn's disease
Suncica Buljevic,Dijana Detel,Ester P. Pugel,Jadranka Varljen
Journal of Cellular Biochemistry.2018;119(8)6743
[DOI]
13Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan
Masato Odawara,Rieko Sagara
Journal of Diabetes & Metabolic Disorders.2015;15(1)6743
[DOI]
Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow